Preclinical Remodeling of Human Prostate Cancer through the PTEN/AKT Pathway

被引：14

作者：

De Velasco, Marco A. ^{[1
,2
]}

Uemura, Hirotsugu ^{[1
]}

机构：

[1] Kinki Univ, Sch Med, Dept Urol, 377-2 Ohno Higashi, Sayama, Osaka 5898511, Japan

[2] Kinki Univ, Sch Med, Dept Genome Biol, Sayama, Osaka 5898511, Japan

来源：

ADVANCES IN UROLOGY | 2012年 / 2012卷

基金：

日本学术振兴会;

关键词：

D O I：

10.1155/2012/419348

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

Knowledge gained from the identification of genetic and epigenetic alterations that contribute to the progression of prostate cancer in humans is now being implemented in the development of functionally relevant translational models. GEM (genetically modified mouse) models are being developed to incorporate the same molecular defects associated with human prostate cancer. Haploinsufficiency is common in prostate cancer and homozygous loss of PTEN is strongly correlated with advanced disease. In this paper, we discuss the evolution of the PTEN knockout mouse and the cooperation between PTEN and other genetic alterations in tumor development and progression. Additionally, we will outline key points that make these models key players in the development of personalized medicine, as potential tools for target and biomarker development and validation as well as models for drug discovery.

引用

页数：12

共 132 条

[1]

Abate-Shen C, 2003, CANCER RES, V63, P3886

[2] Molecular genetics of prostate cancer [J].

Abate-Shen, C ;

Shen, MM .

GENES & DEVELOPMENT, 2000, 14 (19) :2410-2434

[3] Stat3 promotes metastatic progression of prostate cancer [J].

Abdulghani, Junaid ;

Gu, Lei ;

Dagvadorj, Ayush ;

Lutz, Jacqueline ;

Leiby, Benjamin ;

Bonuccelli, Gloria ;

Lisanti, Michael P. ;

Zellweger, Tobias ;

Alanen, Kalle ;

Mirtti, Tuomas ;

Visakorpi, Tapio ;

Bubendorf, Lukas ;

Nevalainen, Marja T. .

AMERICAN JOURNAL OF PATHOLOGY, 2008, 172 (06) :1717-1728

[4] Conditional loss of Nkx3.1 in adult mice induces prostatic intraepithelial neoplasia [J].

Abdulkadir, SA ;

Magee, JA ;

Peters, TJ ;

Kaleem, Z ;

Naughton, CK ;

Humphrey, PA ;

Milbrandt, J .

MOLECULAR AND CELLULAR BIOLOGY, 2002, 22 (05) :1495-1503

[5]

Ahmad Imran, 2008, Expert Reviews in Molecular Medicine, V10, P1, DOI 10.1017/S1462399408000689

[6] Pilot study of rapamycin in patients with hormone-refractory prostate cancer [J].

Amato, Robert J. ;

Jac, Jaroslaw ;

Mohammad, Taqi ;

Saxena, Somya .

CLINICAL GENITOURINARY CANCER, 2008, 6 (02) :97-102

[7] Early onset of neoplasia in the prostate and skin of mice with tissue-specific deletion of Pten [J].

Backman, SA ;

Ghazarian, D ;

So, K ;

Sanchez, O ;

Wagner, KU ;

Hennighausen, L ;

Suzuki, A ;

Tsao, MS ;

Chapman, WB ;

Stambolic, V ;

Mak, TW .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 (06) :1725-1730

[8] New Therapies for Castration-Resistant Prostate Cancer: Efficacy and Safety [J].

Beltran, Himisha ;

Beer, Tomasz M. ;

Carducci, Michael A. ;

de Bono, Johann ;

Gleave, Martin ;

Hussain, Maha ;

Kelly, William K. ;

Saad, Fred ;

Sternberg, Cora ;

Tagawa, Scott T. ;

Tannock, Ian F. .

EUROPEAN UROLOGY, 2011, 60 (02) :279-290

[9] Expression signature of the mouse prostate [J].

Berquin, IM ;

Min, YN ;

Wu, RP ;

Wu, H ;

Chen, YQ .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2005, 280 (43) :36442-36451

[10] Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: Updated survival in the TAX 327 study [J].

Berthold, Dominik R. ;

Pond, Gregory R. ;

Soban, Freidele ;

de Wit, Ronald ;

Eisenberger, Mario ;

Tannock, Ian F. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (02) :242-245

← 1 2 3 4 5 6 7 8 9 10 →